Overview

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of linagliptin and metformin compared to the administration of two single tablets (linagliptin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patients' compliance with antidiabetic treatment., in particular with concern to the frequent polypharmacy in diabetic patients.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Linagliptin
Metformin